Impress employers and recruiters.
Choose from hundreds of resume examples.
Impress employers and recruiters.
Choose from hundreds of resume examples.
Tailor your resume to this BD&Ops Director / Sr. Director role.
Rezi rewrites your resume against BridgeBio Pharma's job description. Free.
Tailor your resume to this BD&Ops Director / Sr. Director role.
Rezi rewrites your resume against BridgeBio Pharma's job description. Free.
Don't guess if your resume is good enough.
See how it scores against the BD&Ops Director / Sr. Director posting at BridgeBio Pharma — free, in seconds.
Don't guess if your resume is good enough.
See how it scores against the BD&Ops Director / Sr. Director posting at BridgeBio Pharma — free, in seconds.
About the Role
BridgeBio is a biopharmaceutical company focused on developing transformative medicines for genetic diseases and cancers. Evanesco Therapeutics, an affiliate, is developing a next-generation antibody therapeutic for transthyretin amyloid cardiomyopathy (ATTR-CM), aiming to clear amyloid deposits in the heart. This role offers direct impact from preclinical data to clinical strategy within a fast-moving, autonomous team.
Responsibilities
- Set, prioritize, and manage milestones & deliverables for team members in one or more subsidiary companies.
- Coordinate team meetings and delegate to technical experts in one or more subsidiary companies.
- Interpret, collate, and communicate critical data findings concisely to senior management.
- Identify problems, locate resources, and find data-driven solutions independently.
Requirements
- Ph.D. from a top-tier academic institution, or a scientific undergraduate degree with commensurate work experience.
- Operating/program management experience working with a close-knit team at a biotech startup or top-tier pharma.
- Management Consulting or Banking experience from a leading tier firm.
Skills
- Patient-driven mindset
- Detailed curiosity for science
- Demonstrated ability to thrive in an intense environment
- Comfortable improvising amid ambiguity in drug development
- Confidence to chart own course
- Unrivaled sense of urgency
Location
- San Francisco, CA
Work Type
- Hybrid
Experience Level
- Commensurate work experience
Education Level
- Ph.D.
- Scientific undergraduate degree
Salary/Compensations
- $220,000—$300,000 USD
Benefits
- Market-leading compensation
- 401(k) with employer match
- Employee Stock Purchase Program (ESPP)
- Pre-tax commuter benefits
- Referral bonus
- Subsidized lunch and parking on in-office days
- 100% employer-paid medical, dental, and vision premiums for employee and dependents
- Health Savings Account (HSA) with annual employer contributions
- Flexible Spending Accounts (FSA)
- Fertility & family-forming benefits
- Expanded mental health support
- Hybrid work model with flexibility
- Flexible, take-what-you-need paid time off
- Company-paid holidays
- Comprehensive paid medical and parental leave
- Endless opportunities for skill development and internal mobility
- Career pathing through regular feedback, continuous education and professional development programs
- Celebration of strong performance with financial rewards, peer-to-peer recognition, and growth opportunities
About the Company
- BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers.
- We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients.
- Founded in 2015, the company has built a portfolio of 20+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology and renal disease, with two approved drugs.
- Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines.
- We have U.S. offices in San Francisco, Palo Alto, Raleigh, with small satellites in other parts of the country.
- We also have international offices in Montreal, Canada and Zurich, Switzerland, and are expanding across Europe.
- Evanesco Therapeutics is a BridgeBio affiliate developing a next-generation monoclonal antibody depleter for transthyretin amyloid cardiomyopathy (ATTR-CM).
- Unlike approved therapies that stabilize transthyretin or reduce its production, our approach is designed to clear amyloid already deposited in the heart.
- We recently achieved development candidate nomination and are preparing for IND submission, with first-in-human studies to follow.
- This is a small, fast-moving team operating with startup autonomy inside an established company.
Equal Opportunity
- By applying, you acknowledge that BridgeBio will process your personal information as described in our Global Candidate Privacy Notice.